ERBB2 and breast carcinoma: Based on the results, as of 2024, the National Comprehensive Cancer Network (NCCN) guidelines state that systemic therapy with T-DXd or tucatinib may be administered for HER2 breast cancer BMs that do not require urgent local therapy [14].